Moleculin’s Brain Cancer Drug Candidate Begins Patient Dosing at Clinical Trial Being Conducted at MD Anderson Sep 13, 2018
Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2018 Aug 13, 2018
Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia Jul 18, 2018
Moleculin Expands Operations to Australia; Taps R&D Incentive Program Capped at $20,000,000 AUD Turnover Jul 11, 2018
Moleculin Targets accelerated FDA approval of WP1732; Pursues Development for Ocular Tumors Jun 12, 2018
